Clinical trials
Locally Advanced Prostate Carcinoma clinical trials
Below are recruiting locally advanced prostate carcinoma clinical trials, each written for real people, not researchers. We’re tracking 170 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06807359RecruitingPhase 1/Phase 2
Light-activated therapy for localized prostate cancer
This trial uses a special light-activated drug (photodynamic therapy) to treat prostate cancer that is still confined to the prostate. It aims to destroy the cancer while sparing healthy tissue, and may be an option for people with intermediate-risk prostate cancer who have not had other treatments.
New York, New YorkAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Phoenix, ArizonaAges 18 years+ - NCT06742892RecruitingPhase 2
Study of HLX43 for advanced liver cancer after standard treatment fails
This trial tests a new drug, HLX43, for people with advanced liver cancer (HCC) that has worsened or caused intolerable side effects after standard treatments like immunotherapy or targeted therapy. The goal is to see if HLX43 can help when other options have stopped working.
Hunan, HunanAges 18–75 - NCT06211114RecruitingPhase 2
Immunotherapy and targeted drug for advanced collecting duct kidney cancer
This trial tests a combination of immunotherapy and a targeted drug (axitinib) for people with advanced collecting duct carcinoma, a rare type of kidney cancer. The goal is to see if this treatment can shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–80 - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Birmingham, AlabamaAges Any age - NCT05661461RecruitingPhase 1
Test drug dosing and safety for advanced cancers with liver issues
This Phase 1 study tests different doses of nab-sirolimus to see if it is safe and how the body processes it. It is for people with advanced or metastatic solid tumors who also have moderate liver impairment.
San Antonio, TexasAges 18 years+ - NCT06346197RecruitingPhase 3
Immunotherapy combo for advanced MSI-H stomach/esophageal cancer
This trial tests a combination of immune checkpoint inhibitors (nivolumab, botensilimab, and balstilimab) plus chemotherapy for people with advanced stomach or esophageal cancer that has a specific genetic instability (MSI-H/dMMR) and expresses PD-L1. It may be an option for those who haven't had prior immunotherapy or chemotherapy for advanced disease.
BrestAges 18 years+ - NCT05706129RecruitingPhase 1/Phase 2
Testing targeted imaging and therapy for advanced solid tumors
This early-phase study tests two radioactive medicines that first help doctors see tumors and, in some parts of the study, treat them. It may help people with advanced, hard-to-remove cancers that have a specific tumor marker (CA IX).
MelbourneAges 18 years+ - NCT07454642RecruitingPhase 1
AVA6103 for advanced FAP-positive solid tumors
This trial tests a new drug called AVA6103 for certain advanced cancers that show a protein called FAP. It is for people who have already tried other treatments or cannot take them, and aims to see if the drug is safe and helps shrink tumors.
Grand Rapids, MichiganAges 18 years+ - NCT06778863RecruitingPhase 1
A study of CLSP-1025 for adults with certain solid tumors
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
Scottsdale, ArizonaAges 18 years+ - NCT05866692RecruitingPhase 1
First-in-human capsule for advanced solid tumors
This Phase 1 study tests a new oral capsule (TY-2699a) in people with advanced or metastatic solid tumors that have limited treatment options. It will look for the safest dose and whether the drug can shrink tumors, especially in certain genetic/biomarker patterns.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05715931RecruitingPhase 2
Surgery chemotherapy plus anti-HER2 and anti–immune therapy for HER2 stomach cancer
This Phase 2 trial tests adding chemotherapy plus trastuzumab and toripalimab around the time of surgery for HER2-positive, locally advanced stomach or esophagus-stomach junction cancer. It aims to shrink the cancer and reduce the chance it comes back by attacking it through more than one pathway.
Hangzhou, ZhejiangAges 18–80 - NCT03257033RecruitingPhase 3
Gemcitabine through an artery versus by vein after radiation
This study tests whether giving gemcitabine directly into the artery feeding the pancreas (instead of through an IV) works better after you finish radiation therapy. It may help patients by improving how the medicine reaches the tumor while comparing side effects and outcomes between the two delivery methods.
Loma Linda, CaliforniaAges 18 years+ - NCT06250036RecruitingPhase 2
Immunotherapy before surgery for MMRd stomach cancer
This trial tests two immunotherapy drugs, zimberelimab and domvanalimab, given before surgery for people with a specific type of stomach cancer (called MMRd/MSI-H). The goal is to see if these drugs can shrink the tumor and improve outcomes.
Cambridge, CambridgeshireAges 18 years+ - NCT05872685RecruitingPhase 2
Perioperative chemo plus serplulimab for specific stomach cancers
This Phase 2 trial tests whether adding serplulimab (an immune medicine) to standard chemotherapy before and/or around surgery can improve outcomes for people with certain locally advanced stomach cancer. You may get serplulimab or a placebo, and researchers will compare results to see if the immune add-on helps.
Hangzhou, ZhejiangAges 18–80 - NCT05729646RecruitingPhase 2
Pre-surgery chemotherapy with toripalimab for dMMR stomach cancer
This trial studies whether adding toripalimab (an immune therapy) to chemotherapy before and around surgery can improve outcomes for people with certain mismatch repair–deficient stomach cancers. It mainly targets tumors that are dMMR and not HER2-positive.
Hangzhou, ZhejiangAges 18–80 - NCT07699939RecruitingPhase 2
Perioperative immunotherapy plus chemo for advanced gastric cancer
This trial tests whether adding the immunotherapy drug HLX10 (serplulimab) to standard chemotherapy (S-1 plus oxaliplatin) before and after surgery can improve outcomes for patients with advanced gastric or gastroesophageal junction cancer that has a high level of PD-L1 protein.
Chiba, ChibaAges 18–80 - NCT05785039RecruitingPhase 2
Study drug for advanced bladder and other solid cancers
This Phase 2 trial tests BL-B01D1 to treat people with advanced or metastatic urothelial (urinary tract) cancer and other solid tumors. You may be eligible if standard treatments are no longer working or are not available, and you can meet safety and cancer-measurement requirements.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT06358677RecruitingPhase 2
Tretinoin cream to prevent skin rash from EGFR drugs
This study tests whether a topical tretinoin cream can prevent the skin rash often caused by anti-EGFR drugs like panitumumab or cetuximab. It is for people with advanced solid tumors who are about to start one of these treatments.
Salt Lake City, UtahAges 18 years+ - NCT06415318RecruitingPhase 2
TIP chemo plus triplizumab before surgery for penile cancer
This trial tests a combination of chemotherapy drugs (paclitaxel, ifosfamide, cisplatin) and an immunotherapy drug (triplizumab) given before surgery for locally advanced penile cancer. The goal is to shrink the tumor and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT06524167Recruiting
Radiation therapy after surgery for advanced thyroid cancer
This study looks at whether adding radiation therapy after surgery can help people with thyroid cancer that is at high risk of coming back. It includes different types of thyroid cancer, like differentiated and medullary types.
ShanghaiAges 14–80 - NCT06558981RecruitingPhase 3
Radiation therapy after thyroid surgery for high-risk cancer
This trial is testing whether giving radiation therapy after thyroid surgery can help destroy any leftover cancer cells in people with high-risk differentiated thyroid cancer. It is for those who had surgery but some cancer was still left behind.
ShanghaiAges 14–80 - NCT06567015RecruitingPhase 1/Phase 2
STX-241 for advanced EGFR-mutant lung cancer after TKI failure
This trial tests an experimental drug called STX-241 for people with a specific type of advanced lung cancer (NSCLC) that has an EGFR mutation (exon 19 deletion or L858R) and has stopped responding to a third-generation EGFR inhibitor (like osimertinib). The drug aims to target a new mutation, C797X, that sometimes appears after osimertinib stops working.
Nashville, TennesseeAges 18 years+
Hear when a new Locally Advanced Prostate Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced prostate carcinoma?
- Yes. Clin2 currently lists 170 recruiting locally advanced prostate carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced prostate carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced prostate carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced Rectal Carcinoma
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- Locally Advanced Nasopharyngeal Carcinoma
- Locally Advanced Cervical Carcinoma
- Locally Advanced Esophageal Squamous Cell Carcinoma
- Locally Advanced Hepatocellular Carcinoma
- Locally Advanced Lung Non-Small Cell Carcinoma
- Locally Advanced Prostate Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.